Clinical trials: Chronic Constipation
Chronic Idiopathic Constipation
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
To evaluate the pharmacodynamics and tolerability of a liquid formulation of lubiprostone, as compared to matching placebo, when administered orally to subjects with chronic idiopathic constipation.
- Trial name
- NCT01993875
- Testing
- Lubiprostone
- Where
- 11 sites in United States
- Volunteers
- 164 people
- Sponsor
- Mallinckrodt
Chronic Constipation
Trial of Linaclotide in Patients With Chronic Constipation
The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC).
- Trial name
- NCT00730015
- Testing
- Linaclotide
- Where
- 105 sites in United States
- Volunteers
- 643 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Chronic Idiopathic Constipation
Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo
The purpose of this study is to evaluate the bioequivalence of sprinkle and capsule formulations of lubiprostone, as compared to placebo, when administered orally in participants with Chronic Idiopathic Constipation (CIC).
- Trial name
- NCT03097861
- Testing
- Lubiprostone
- Where
- 67 sites in United States
- Volunteers
- 552 people
- Sponsor
- Sucampo Pharma Americas, LLC
Opioid-Induced Constipation
A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain
MNTX 3201 is a Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of oral MNTX for the treatment of opioid induced constipation in…
- Trial name
- NCT01186770
- Testing
- Methylnaltrexone
- Where
- 2 sites in United States
- Volunteers
- 804 people
- Sponsor
- Bausch Health Americas, Inc.
Constipation
Effect Comparison of Electro-acupuncture and Prucalopride for Severe Chronic Constipation: a Randomized Controlled Trial
This trial is primarily aimed to compare the effect and safety of electro-acupuncture and prucalopride for severe chronic constipation: if the short-term effect of electro-acupuncture is no inferior to prucalopride? Besides, the…
- Trial name
- NCT02047045
- Testing
- acupuncture, Prucalopride
- Volunteers
- 560 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Chronic Idiopathic Constipation
Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation
The purpose of this study is to determine if lubiprostone may change the rate of movement of food and activities in the stomach and intestines in subjects whose gastrointestinal (GI) tract is slower due to constipation.
- Trial name
- NCT01469819
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Opioid Induced Bowel Dysfunction
Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain
The primary objective of the study is to evaluate the safety of single doses of oral naldemedine in adults physically dependent on opioids.
- Trial name
- NCT01122030
- Testing
- Naldemedine
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Shionogi
Chronic Idiopathic Constipation
12-Week Study of Plecanatide for CIC (The CIC3 Study)
The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.
- Trial name
- NCT01982240
- Testing
- Plecanatide, Bisacodyl
- Where
- 189 sites in United States, Canada
- Volunteers
- 1,394 people
- Sponsor
- Bausch Health Americas, Inc.
Constipation
Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Morphine and related opioid analgesics are known to slow gastrointestinal (GI) motility and reduce intestinal secretion through their binding to μ opioid receptors (MORs) within the GI tract.
- Trial name
- NCT01275755
- Testing
- ADL5945 0.25 mg
- Volunteers
- 81 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Opioid Induced Constipation
Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Morphine and related opioid analgesics are known to slow gastrointestinal (GI) motility and reduce intestinal secretion through their binding to μ opioid receptors (MORs) within the GI tract.
- Trial name
- NCT01207427
- Testing
- ADL5945 0.1 mg, ADL5945 0.25 mg
- Volunteers
- 131 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Opioid-Induced Constipation
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
The purpose of this study was to evaluate the safety and efficacy of linaclotide for the treatment of opioid-induced constipation (OIC), in adults receiving stable opioid treatment for chronic non-cancer pain that has been…
- Trial name
- NCT02270983
- Testing
- Linaclotide 145 micrograms, Linaclotide 290 micrograms
- Where
- 77 sites in United States
- Volunteers
- 254 people
- Sponsor
- Forest Laboratories
Chronic Idiopathic Constipation
Efficacy and Safety of Vibrant Capsule vs. Placebo for the Treatment of Chronic Idiopathic Constipation
The study is a prospective, randomized, multicenter, adaptive design, double blinded, placebo-controlled study, to evaluate the efficacy and safety of Vibrant Capsule vs.
- Trial name
- Vibrant (NCT03879239)
- Testing
- Vibrating capsule
- Where
- 8 sites in United States
- Volunteers
- 349 people
- Sponsor
- Vibrant Ltd.
Constipation
Lubiprostone and Mucus Secretion in Patients With Chronic Constipation
The investigators hypothesize that the symptoms of chronic constipation in some patients are developed due to diminished production and secretion of the alimentary tract mucus resulting in poor lubrication.
- Trial name
- NCT01447849
- Testing
- lubiprostone
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Constipation
Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain
The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects with chronic pain, which is not due to…
- Trial name
- NCT00547586
- Testing
- N-methylnaltrexone bromide (MOA-728)
- Where
- 41 sites in United States
- Volunteers
- 122 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Idiopathic Constipation
SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation
This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose ranging study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) effects of SP-304 in patients with chronic…
- Trial name
- CIC (NCT01053962)
- Testing
- SP-304 0.3 mg, SP-304 1.0 mg, SP-304 3.0 mg
- Where
- 14 sites in United States
- Volunteers
- 84 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Constipation, Irritable Bowel Syndrome With Constipation
An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).
- Trial name
- NCT00765999
- Testing
- Linaclotide
- Where
- 118 sites in United States, Canada
- Volunteers
- 1,559 people
- Sponsor
- Forest Laboratories
Chronic Idiopathic Constipation
Efficacy of Linaclotide to Senna for CIC
In this prospective, randomized, double blind study, the aim is to determine the efficacy of Linaclotide in relation to Senna in relieving the symptoms of chronic idiopathic constipation (CIC).
- Trial name
- NCT02239510
- Testing
- Senna, Linzess
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- TriHealth Inc.
Opioid-induced Constipation
Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation
The purpose of this study is to evaluate the efficacy and safety of naldemedine in the treatment of opioid-induced constipation (OIC) in adults with non-malignant chronic pain who are not using laxatives.
- Trial name
- NCT01965158
- Testing
- Naldemedine
- Where
- 65 sites in United States, Austria and 5 more
- Volunteers
- 547 people
- Sponsor
- Shionogi
Chronic Constipation
Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation
The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC).
- Trial name
- NCT00765882
- Testing
- Linaclotide 290 micrograms, Linaclotide 145 micrograms
- Where
- 108 sites in United States, Canada
- Volunteers
- 633 people
- Sponsor
- Forest Laboratories
Chronic Constipation, Constipation
Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating
The purpose of this study is to evaluate the efficacy and safety of linaclotide compared with placebo in patients with chronic constipation (CC) and prominent abdominal bloating.
- Trial name
- NCT01642914
- Testing
- Linaclotide 290 micrograms, Linaclotide 145 micrograms
- Where
- 151 sites in United States, Canada
- Volunteers
- 487 people, healthy volunteers welcome
- Sponsor
- Forest Laboratories